MCM
CORT icon

MAI Capital Management’s Corcept Therapeutics CORT Stock Holding History

MAI Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$416K Buy
4,786
+4,737
+9,667% +$286K ﹤0.01% 1402
2026
Q1 		$1.98K Buy
49
+36
+277% +$1.35K ﹤0.01% 3932
2025
Q4 		$453 Sell
13
-129
-91% -$10.1K ﹤0.01% 3860
2025
Q3 		$11.8K Sell
142
-142
-50% -$10.3K ﹤0.01% 2673
2025
Q2 		$20.8K Buy
+284
New +$20.6K ﹤0.01% 2330

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAI Capital Management's CORT Position: Q2 2026 in Review

MAI Capital Management increased its Corcept Therapeutics (CORT) stake by 9,667% in Q2 2026, buying an estimated $286K and bringing the position to 4,786 shares worth $416K. The position accounts for ﹤0.01% of the portfolio, ranked #1402.

MAI Capital Management first reported a position in CORT in Q2 2025 and has held it in 5 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • MAI Capital Management held 4,786 shares of Corcept Therapeutics worth $416K as of Q2 2026.
  • MAI Capital Management bought 4,737 Corcept Therapeutics shares in Q2 2026, an estimated $286K.
  • Corcept Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1402 holding.
  • MAI Capital Management first reported a position in Corcept Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.